Analysis of tumor infiltration using conventional methods reveals a snapshot view of
lymphocyte interactions with the tumor environment. However, lymphocytes have the unique …

Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune
therapies limits the benefits of current treatments. Identifying and adding anti‐resistance …

Pancreatic cancer is a lethal disease, harboring a five-year overall survival rate of only 13%.
Current treatment approaches thus require modulation, with attention shifting towards …

Metastasis is an important cause of cancer-related death. Immunotherapy may be an
effective way to prevent and treat tumor metastasis in the future. Currently, many studies …

Immunotherapy for cancer has provided new treatment approaches for malignant tumors,
but there are low rates of response and high rates of resistance. The most recent …

The clinical response to cancer therapies involves the complex interplay between the
systemic, tumoral, and stromal immune response as well as the direct impact of treatments …

Intratumoral B cell responses are associated with more favorable clinical outcomes in
human pancreatic ductal adenocarcinoma (PDAC). However, the antigens driving these B …

Background Tumor-specific neoantigens are ideal targets for cancer immunotherapy. As
research findings have proved, neoantigen-specific T cell activity is immunotherapy's most …

Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib
improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b …

In the tumor microenvironment, tumor-infiltrating immune cells (TIICs) are a key component.
Different types of TIICs play distinct roles. CD8+ T cells and natural killer (NK) cells could …